MENLO PARK, Calif.--(BUSINESS WIRE)--Mar. 12, 2024--
Sofinnova Investments, a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor. In this role, he will be advising Sofinnova’s portfolio companies on corporate and financial strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312683597/en/
Troy Ignelzi, Executive Advisor, Sofinnova Investments (Photo: Business Wire)
Mr. Ignelzi brings to Sofinnova over two decades of financial leadership experience in the biotech and pharmaceuticals sectors. He is currently Chief Financial Officer at Rapport Therapeutics, a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines. Over the course of his career, Mr. Ignelzi has raised an impressive $4 billion-plus in capital for life science companies.
Prior to joining Rapport Therapeutics, he was Chief Financial Officer at Karuna Therapeutics, where he led the team in the execution of a private crossover round, the company’s IPO and multiple follow-on financings. Prior to Karuna, Mr. Ignelzi served as Chief Financial Officer at two other companies, Juventas Therapeutics and scPharmaceuticals.
“We’ve had the pleasure of knowing Troy for a number of years as he has held leadership and Board positions across several of our portfolio companies including Karuna, CinCor and now Rapport Therapeutics. We are extremely pleased to have him join us,” said Jim Healy, M.D., Ph.D., Managing Partner, Sofinnova Investments. “He brings invaluable experience across finance, business development, and operations to our portfolio companies, and has led several privately-held clinical-stage organizations to become publicly-traded companies preparing for commercial launch.”
“I look forward to supporting Sofinnova Investments’ portfolio companies as an executive advisor and contributing to the long-term success of the organization and helping bring novel therapies to patients,” said Mr. Ignelzi. “I could not be more excited to work with the team as we continue to build and support companies to improve patient lives.”
Mr. Ignelzi has a long track record of experience in the sector, having started out at Eli Lilly and then moving on to roles of increasing responsibility at companies including Esperion Therapeutics and the former Insys Therapeutics. Previously, Mr. Ignelzi served on the board of CinCor Pharma, Inc., where he advised on the company’s sale to AstraZeneca in early 2023. He currently serves on the boards of Vedanta Biosciences and Abivax (Nasdaq: ABVX). He is a graduate of Ferris State University, where he earned his B.S. in accounting.
About Sofinnova Investments
Sofinnova Investments is a healthcare investment firm committed to funding innovative products that aspire to meaningfully impact the lives of patients. We invest in both private and public equity companies. Sofinnova actively partners with entrepreneurs across all stages of company formation, we are long-term investors with extensive scientific expertise, vast industry knowledge, and a track record of helping forge the path from drug development and navigating the regulatory process to company building and IPO or M&A.
Founded in 1976, Sofinnova has a long legacy of building what we believe are great companies in both the U.S. and Europe with approximately $3.7B in assets under management and committed capital as of 12/31/2023. For more information, please visit www.sofinnova.com.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20240312683597/en/
Sofinnova Investments
Tiffany Davis
davis@sofinnova.com
Media Contact
Kimberly Ha
KKH Advisors
kimberly.ha@kkhadvisors.com
Source: Sofinnova Investments
